Top

BMC Cardiovascular Disorders

Published in:

Open Access 01-12-2021 | Fatty Liver | Research

Severe, but not mild to moderate, non-alcoholic fatty liver disease associated with increased risk of subclinical coronary atherosclerosis

Authors: Chia-Chi Hsiao, Pai-Hsueh Teng, Yun-Ju Wu, Yi-Wen Shen, Guang-Yuan Mar, Fu-Zong Wu

Published in: BMC Cardiovascular Disorders | Issue 1/2021

Abstract

Background

Non-alcoholic fatty liver disease (NAFLD) is associated with high risk of cardiovascular disease. The prevalence is increasing to 45–65% in the general population with routine health check-up, and most subjects have the mild degree NAFLD in recent years. Moreover, there are no studies on the association between NAFLD severity and coronary atherosclerosis in the real-world setting by ultrasonography.

Methods

The aim of this study was to determine the relationship between the severity of NAFLD and subclinical coronary atherosclerosis. Overall, 817 subjects meet criteria for NAFLD were enrolled in the retrospective cohort study (155 subjects were excluded). The severity of NAFLD was divided into the normal, mild, moderate and severe degree based on the finding of abdominal ultrasonography. The assessment of coronary atherosclerosis was based on CAC scan/coronary CT angiography finding in terms of CAC score ≧ 100, CAC score ≧ 400, CAD-RADS ≧ 3 and presence of vulnerable plaque(s).

Results

A significant linear trend was observed between the severity of NAFLD and subclinical coronary atherosclerosis. Compared with the reference group (including normal, mild, and moderate NAFLD), severe degree NAFLD was the independently associated risk of subclinical coronary atherosclerosis in term of CAC score ≧ 100, CAC score ≧ 400, CAD-RADS ≧ 3 and presence of vulnerable plaque(s) based on binary logistic regression after adjustment for FRS score and body fat percentage.

Conclusions

Severe degree, but not mild to moderate, was associated with high risk of subclinical coronary atherosclerosis, independently of FRS score and body-fat percentage.

Available only for authorised users

Araújo AR, Rosso N, Bedogni G, Tiribelli C, Bellentani S. Global epidemiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: What we need in the future. Liver Int. 2018;38(S1):47–51.PubMedCrossRef

Younossi ZM. Non-alcoholic fatty liver disease & #x2013; A global public health perspective. J Hepatol. 2019;70(3):531–44.PubMedCrossRef

Mitra S, De A, Chowdhury A. Epidemiology of non-alcoholic and alcoholic fatty liver diseases. Transl Gastroenterol Hepatol. 2020;5:16–16.PubMedPubMedCentralCrossRef

Andronescu CI, Purcarea MR, Babes PA. Nonalcoholic fatty liver disease: epidemiology, pathogenesis and therapeutic implications. J Med Life. 2018;11(1):20–3.PubMedPubMedCentral

Lonardo A, Ballestri S, Marchesini G, Angulo P, Loria P. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Dig Liver Dis. 2015;47(3):181–90.PubMedCrossRef

Abdallah LR, de Matos RC, e Souza YPDM, Vieira-Soares D, Muller-Machado G, Pollo-Flores P. Non-alcoholic Fatty Liver Disease and Its Links with Inflammation and Atherosclerosis. Curr Atheroscler Rep. 2020;22(1):7.PubMedCrossRef

Wu F-Z, Chou K-J, Huang Y-L, Wu M-T. The relation of location-specific epicardial adipose tissue thickness and obstructive coronary artery disease: systemic review and meta-analysis of observational studies. BMC Cardiovasc Disord. 2014;14:62–62.PubMedPubMedCentralCrossRef

Lu H, Liu H, Hu F, Zou L, Luo S, Sun L. Independent association between nonalcoholic fatty liver disease and cardiovascular disease: a systematic review and meta-analysis. Int J Endocrinol. 2013;2013:124958–124958.PubMedPubMedCentralCrossRef

Jaruvongvanich V, Wirunsawanya K, Sanguankeo A, Upala S. Nonalcoholic fatty liver disease is associated with coronary artery calcification: a systematic review and meta-analysis. Dig Liver Dis. 2016;48(12):1410–7.PubMedCrossRef

10.

Ampuero J, Gallego-Durán R, Romero-Gómez M. Association of NAFLD with subclinical atherosclerosis and coronary-artery disease: meta-analysis. Rev Esp Enferm Dig. 2015;107(1):10–6.PubMed

11.

Inci MF, Özkan F, Ark B, Vurdem ÜE, Ege MR, Sincer I, Zorlu A. Sonographic evaluation for predicting the presence and severity of coronary artery disease. Ultrasound Q. 2013;29(2):125–30.PubMedCrossRef

12.

Lee JE, Lee YJ, Chung SY, Cho HW, Park BJ, Jung DH. Severity of nonalcoholic fatty liver disease is associated with subclinical cerebro-cardiovascular atherosclerosis risk in Korean men. PLoS ONE. 2018;13(3):e0193191–e0193191.PubMedPubMedCentralCrossRef

13.

Lazo M, Hernaez R, Eberhardt MS, Bonekamp S, Kamel I, Guallar E, Koteish A, Brancati FL, Clark JM. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988–1994. Am J Epidemiol. 2013;178(1):38–45.PubMedPubMedCentralCrossRef

14.

Hsu C-L, Wu F-Z, Lin K-H, Chen Y-H, Wu P-C, Chen Y-H, Chen C-S, Wang W-H, Mar G-Y, Yu H-C. Role of fatty liver index and metabolic factors in the prediction of nonalcoholic fatty liver disease in a lean population receiving health checkup. Clin Transl Gastroenterol. 2019;10(5):1–8.

15.

Sohn C, Kim J, Bae W. The framingham risk score, diet, and inflammatory markers in Korean men with metabolic syndrome. Nutr Res Pract. 2012;6(3):246–53.PubMedPubMedCentralCrossRef

16.

Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55(6):2005–23.PubMedCrossRef

17.

Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, Mullen KD, Cooper JN, Sheridan MJ. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123(3):745–50.PubMedCrossRef

18.

Cury RC, Abbara S, Achenbach S, Agatston A, Berman DS, Budoff MJ, Dill KE, Jacobs JE, Maroules CD, Rubin GD, et al. Coronary Artery Disease - Reporting and Data System (CAD-RADS): an Expert Consensus Document of SCCT, ACR and NASCI: endorsed by the ACC. JACC Cardiovasc Imaging. 2016;9(9):1099–113.PubMedCrossRef

19.

Rumberger JA, Brundage BH, Rader DJ, Kondos G. Electron beam computed tomographic coronary calcium scanning: a review and guidelines for use in asymptomatic persons. Mayo Clin Proc. 1999;74(3):243–52.PubMedCrossRef

20.

Neves PO, Andrade J, Monção H. Coronary artery calcium score: current status. Radiol Bras. 2017;50(3):182–9.PubMedPubMedCentralCrossRef

21.

Shen YW, Wu YJ, Hung YC, Hsiao CC, Chan SH, Mar GY, Wu MT, Wu FZ. Natural course of coronary artery calcium progression in Asian population with an initial score of zero. BMC Cardiovasc Disord. 2020;20(1):212.PubMedPubMedCentralCrossRef

22.

Liu Y, Zhong G-C, Tan H-Y, Hao F-B, Hu J-J. Nonalcoholic fatty liver disease and mortality from all causes, cardiovascular disease, and cancer: a meta-analysis. Sci Rep. 2019;9(1):11124.PubMedPubMedCentralCrossRef

23.

Mahale AR, Prabhu SD, Nachiappan M, Fernandes M, Ullal S. Clinical relevance of reporting fatty liver on ultrasound in asymptomatic patients during routine health checkups. J Int Med Res. 2018;46(11):4447–54.PubMedPubMedCentralCrossRef

24.

Denkmayr L, Feldman A, Stechemesser L, Eder SK, Zandanell S, Schranz M, Strasser M, Huber-Schönauer U, Buch S, Hampe J, et al. Lean patients with non-alcoholic fatty liver disease have a severe histological phenotype similar to obese patients. J Clin Med. 2018;7(12):562.PubMedCentralCrossRef

25.

Yasutake K, Kohjima M, Kotoh K, Nakashima M, Nakamuta M, Enjoji M. Dietary habits and behaviors associated with nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20(7):1756–67.PubMedPubMedCentralCrossRef

26.

Yilmaz Y, Senates E, Ayyildiz T, Colak Y, Tuncer I, Ovunc AOK, Dolar E, Kalayci C. Characterization of nonalcoholic fatty liver disease unrelated to the metabolic syndrome. Eur J Clin Invest. 2012;42(4):411–8.PubMedCrossRef

27.

Niikura T, Imajo K, Ozaki A, Kobayashi T, Iwaki M, Honda Y, Kessoku T, Ogawa Y, Yoneda M, Kirikoshi H, et al. Coronary artery disease is more severe in patients with non-alcoholic steatohepatitis than fatty liver. Diagnostics (Basel). 2020;10(3):129.CrossRef

28.

Adinolfi LE, Petta S, Fracanzani AL, Coppola C, Narciso V, Nevola R, Rinaldi L, Calvaruso V, Staiano L, Di Marco V, et al. Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: a prospective multicentre study. Atherosclerosis. 2020;296:40–7.PubMedCrossRef

29.

Adinolfi LE, Petta S, Fracanzani AL, Nevola R, Coppola C, Narciso V, Rinaldi L, Calvaruso V, Pafundi PC, Lombardi R, et al. Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct-acting antiviral therapy: a prospective study. Diabetes Obes Metab. 2020;22(12):2408–16.PubMedCrossRef

30.

Cozzolino D, Sessa G, Salvatore T, Sasso FC, Giugliano D, Lefebvre PJ, Torella R. The involvement of the opioid system in human obesity: a study in normal weight relatives of obese people. J Clin Endocrinol Metab. 1996;81(2):713–8.PubMed

31.

Esposito K, Ciotola M, Sasso FC, Cozzolino D, Saccomanno F, Assaloni R, Ceriello A, Giugliano D. Effect of a single high-fat meal on endothelial function in patients with the metabolic syndrome: role of tumor necrosis factor-alpha. Nutr Metab Cardiovasc Dis. 2007;17(4):274–9.PubMedCrossRef

32.

Marfella R. D’ Amico M, Di Filippo C, Siniscalchi M, Sasso FC, Ferraraccio F, Rossi F, Paolisso G: The possible role of the ubiquitin proteasome system in the development of atherosclerosis in diabetes. Cardiovasc Diabetol. 2007;6:35–35.PubMedPubMedCentralCrossRef

33.

Marfella R, Ferraraccio F, Rizzo MR, Portoghese M, Barbieri M, Basilio C, Nersita R, Siniscalchi LI, Sasso FC, Ambrosino I, et al. Innate immune activity in plaque of patients with untreated and L-thyroxine-treated subclinical hypothyroidism. J Clin Endocrinol Metab. 2011;96(4):1015–20.PubMedCrossRef

34.

Torella D, Ellison GM, Torella M, Vicinanza C, Aquila I, Iaconetti C, Scalise M, Marino F, Henning BJ, Lewis FC, et al. Carbonic anhydrase activation is associated with worsened pathological remodeling in human ischemic diabetic cardiomyopathy. J Am Heart Assoc. 2014;3(2):e000434.PubMedPubMedCentralCrossRef

35.

Minutolo R, Gabbai FB, Provenzano M, Chiodini P, Borrelli S, Garofalo C, Sasso FC, Santoro D, Bellizzi V, Conte G, et al. Cardiorenal prognosis by residual proteinuria level in diabetic chronic kidney disease: pooled analysis of four cohort studies. Nephrol Dial Transplant. 2018;33(11):1942–9.PubMedCrossRef

36.

Sasso FC, Pafundi PC, Marfella R, Calabrò P, Piscione F, Furbatto F, Esposito G, Galiero R, Gragnano F, Rinaldi L, et al. Adiponectin and insulin resistance are related to restenosis and overall new PCI in subjects with normal glucose tolerance: the prospective AIRE Study. Cardiovasc Diabetol. 2019;18(1):24.PubMedPubMedCentralCrossRef

37.

Cengiz M, Sentürk S, Cetin B, Bayrak AH, Bilek SU. Sonographic assessment of fatty liver: intraobserver and interobserver variability. Int J Clin Exp Med. 2014;7(12):5453–60.PubMedPubMedCentral

38.

Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, Guallar E, Clark JM. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology (Baltimore, MD). 2011;54(3):1082–90.CrossRef

39.

van der Wall EE. Screening in asymptomatic coronary artery disease: helpful, redundant or harmful? Neth Hear J. 2014;22(12):531–2.CrossRef

40.

Taylor AJ, Cerqueira M, Hodgson JM, Mark D, Min J, O’Gara P, Rubin GD. ACCF/SCCT/ACR/AHA/ASE/ASNC/NASCI/SCAI/SCMR 2010 appropriate use criteria for cardiac computed tomography. Circulation. 2010;122(21):e525–55.PubMed

41.

Jin KN, Chun EJ, Lee CH, Kim JA, Lee MS, Choi SI. Subclinical coronary atherosclerosis in young adults: prevalence, characteristics, predictors with coronary computed tomography angiography. Int J Cardiovasc Imaging. 2012;28(Suppl 2):93–100.PubMedCrossRef

42.

Noh DW, Kim S. Associations between coronary artery stenosis detected by coronary computed tomography angiography and the characteristics of health checkup examinees in the Republic of Korea. Radiography (Lond). 2020;26(1):22–6.CrossRef

43.

Plank F, Friedrich G, Dichtl W, Klauser A, Jaschke W, Franz WM, Feuchtner G. The diagnostic and prognostic value of coronary CT angiography in asymptomatic high-risk patients: a cohort study. Open Heart. 2014;1(1):e000096.PubMedPubMedCentralCrossRef

44.

Han D, Hartaigh B, Gransar H, Lee JH, Rizvi A, Baskaran L, Schulman-Marcus J, Dunning A, Achenbach S, Al-Mallah MH, et al. Incremental prognostic value of coronary computed tomography angiography over coronary calcium scoring for major adverse cardiac events in elderly asymptomatic individuals. Eur Heart J Cardiovasc Imaging. 2018;19(6):675–83.PubMedCrossRef

45.

Wu Y-J, Mar G-Y, Wu M-T, Wu F-Z. A LASSO-derived risk model for subclinical CAC progression in an Asian population with an initial score of zero. Front Cardiovasc Med. 2021;7(385):1–10.

Title: Severe, but not mild to moderate, non-alcoholic fatty liver disease associated with increased risk of subclinical coronary atherosclerosis
Authors: Chia-Chi Hsiao
Pai-Hsueh Teng
Yun-Ju Wu
Yi-Wen Shen
Guang-Yuan Mar
Fu-Zong Wu
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Fatty Liver
CT Angiography
Arterial Occlusive Disease
Published in: BMC Cardiovascular Disorders / Issue 1/2021
Electronic ISSN: 1471-2261
DOI: https://doi.org/10.1186/s12872-021-02060-z

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Severe, but not mild to moderate, non-alcoholic fatty liver disease associated with increased risk of subclinical coronary atherosclerosis

Abstract

Background

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Participation in disease management programs and major adverse cardiac events in patients after acute myocardial infarction: a longitudinal study based on registry data

Predictive value of CHA2DS2-VASc score combined with hs-CRP for new-onset atrial fibrillation in elderly patients with acute myocardial infarction

Complement component 7 is associated with total- and cardiac death in chest-pain patients with suspected acute coronary syndrome

Accuracy of neutrophil to lymphocyte and monocyte to lymphocyte ratios as new inflammatory markers in acute coronary syndrome

Associations between essential medicines and health outcomes for cardiovascular disease

Prognostic nomogram for 30-day mortality of deep vein thrombosis patients in intensive care unit

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page